Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA views Amgen’s Sensipar as a significant therapeutic advance for secondary hyperparathyroidism, NDA review documents state.
You may also be interested in...
Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Population
FDA-crafted labeling for Amgen’s Sensipar anticipates off-label use of the secondary hyperparathyroidism therapy in pre-dialysis patients, review documents for the NDA show.
Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Population
FDA-crafted labeling for Amgen’s Sensipar anticipates off-label use of the secondary hyperparathyroidism therapy in pre-dialysis patients, review documents for the NDA show.
Amgen Highlighting Cinacalcet Ability To Meet New Targets In Guidelines
Amgen’s pre-approval positioning for cinacalcet is focusing on the calcimimetic’s ability to meet the lower target mineral levels set in the National Kidney Foundation’s new guidelines for bone metabolism and disease.